Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I first-in-human study of AKV9 in healthy subjects

Next Previous
Trial Profile

Phase I first-in-human study of AKV9 in healthy subjects

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AKV-9 (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man

Most Recent Events

  • 06 May 2025 According to an AKAVA Therapeutics media release, company is raising capital in a Series A round to fund the Phase 1 study and supportive activities needed for later phase trials.
  • 23 Aug 2023 New trial record
  • 03 Aug 2023 According to an AKAVA Therapeutics media release, the U.S. Food and Drug Administration has cleared Investigational New Drug (IND) application of AKV9 for the treatment of amyotrophic lateral sclerosis (ALS) to proceed with this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top